Every entrepreneur knows that the road to innovation can be filled with unexpected turns and many bumps along the way. For many medical device innovators, the path from ideation to production is constantly rerouting, making it especially hard to succeed. Coming from within the trenches of a large academic institution is often times considered as a roadblock itself. So… where do you start? Where do you turn to find the best pathway from the inside out? How do you drive your idea into disruption?
Join Johnson & Johnson Innovation - JLABS as they welcome experts in the space who share their views on how to tackle the roadblocks along your path, such as:
• Investor Funding and Cost Allocation,
• IoT Integration and Data Security,
• Protecting IP,
• Product Design and Development
• Reimbursement Strategy,
• Competition and Market Attraction,
• And more...
*Please note: This webinar will be a rebroadcast of the recording which took place on November 3rd, 2020.
Dr. Bryant’s primary responsibilities include supporting the advancement of the Ethicon innovation portfolio by devising and carrying out effective regulatory strategies; supporting the growth of the Ethicon franchise by supporting and maintaining global market access; supporting the growth of R&D talent within Ethicon and across the Johnson & Johnson Medical Devices Companies (JJMDC). LaMont serves on both the Ethicon, Inc. Leadership Team to advance the development of both the business and the function and on the JJMDC Regulatory Affairs Leadership Team.
Brian and his Team are responsible for developing and executing Health Economic and Market Access strategies in support of the Global Ethicon Franchise at Johnson & Johnson. Brian has spent over 25 years in healthcare working to improve patient access. Since joining Johnson and Johnson in 1999, he has led in roles in health economics, outcomes research, reimbursement and market access. He has worked extensively in the US and globally in support of new product development, new business development and commercial strategy.
Mary’s career with Johnson & Johnson spans more than 30 years in diverse roles, including those in public relations, organizational and marketing communications, sales, marketing and technical support. She began her career with Johnson & Johnson in 1990 joining Ortho Clinical Diagnostics (OCD) as a technical support representative and assumed roles with increasing responsibility in account management and marketing. In 2001, she joined the communications team as Director of Public Relations for the OCD franchise and then in 2009 moved to Johnson & Johnson Health Care Systems Inc. where she was responsible for the company’s communications strategy and organizational communications.
Thomas leads the Michigan Coulter Translational Research Partnership Program. The Coulter Program is primarily involved with the funding and management of university based medical device development projects with the goal of licensing intellectual property rights to medical device companies or venture backed startups who continue development and bring these devices to market. He has over 30 years of life science industry, consulting, and academic experience with significant experience in business development, new product planning, commercial strategy development, market research, and brand marketing.
Before joining MIT, Ben led product development at large companies and startups at the VP level, often working through international and US joint development partnerships. With a Ph.D. in physics from Cornell, the first half of his career produced diverse products for medical, industrial, and consumer imaging, drawing from the fields of electrical, optical, laser and CMOS sensor engineering. In 2001, he transitioned into biotech, developing instruments for proteomics and cell-based assays before ending up in antibody drug discovery. As a consultant, he has guided technology venture development firms in assessing investment opportunities and developing their IP strategy, and helped a number of life science startups secure SBIR funding.
Darshana is actively involved in all aspects of Fund Management including Investments and Capital Raising. She led Catalyst’s investments in Augmenix Inc. (Acquired by Boston Scientific, NYSE: BSX), nVision Medical (Acquired by Boston Scientific, NYSE: BSX), Maxwell Health (Acquired by Sun Life Financial, NYSE: SLF), Aria CV, Atacor Medical, Panther Therapeutix and Instylla Inc. She was also actively involved with portfolio company Allegro Diagnostics, Inc. (acquired by Veracyte, NASDAQ: VCT). She serves on the Boards of Directors of all the currently active CHV portfolio companies listed above and serves as Chair of the Board of Aria CV.
Tony has 30 years experience in the medical device and pharmaceutical industries with most of his career spent in general management, new product development, and operations. Currently, Tony is CEO of Advanced Chemotherapy Technologies (ACT). In this role Tony has secured $8M in financing and is leading the company to its first human clinical trial for treatment of pancreatic cancer. Prior to ACT, Tony was founder and CEO of Novocor Medical Systems were he raised over $4M in financing and lead the organization to FDA clearance of Hypocore™, a medical device that chills IV fluids to induce therapeutic hypothermia in cardiac arrest patients.
Johnson & Johnson Innovation – JLABS Notice
The views expressed during this event, including during any associated networking and/or individual meetings by anyone other than an employee of Johnson & Johnson Innovation LLC, its parent company or any affiliate companies (herein after referred to as “JJI”) are those of the speakers or experts alone, and such experts or speakers are solely responsible for the information and opinions expressed by them. By hosting this event, the presentations and any associated networking and/or individual meetings, JJI does not endorse the views of the speakers, experts or the attendees, and JJI makes no warranties, express or implied, as to the content, the views, advice or the information
